{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-260640","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-06-08T10:32:15+00:00","discovered_at":"2026-06-08T10:35:00.316349+00:00","generated_at":"2026-06-08T10:35:18.201722+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cullinan presents initial Phase 1 CLN-978 data in SLE and RA at EULAR; 71% SLE response rate, 5 DORIS remissions","bullets":["In SLE (n=18), 10 of 14 patients (71%) with ≥4 weeks follow-up achieved ≥4-point hSLEDAI reduction; 5 attained DORIS remission.","In RA (n=11), disease activity improved in 5 of 7 evaluable patients (71%), including one DAS28-ESR remission at 30 µg target dose.","Peripheral B-cell depletion >80% in 82% of SLE patients; BLOQ depletion in 50% at target doses ≥20 µg. Dose-dependent depletion also seen in tissues.","CRS events in 11 of 29 patients (38%); mostly Grade 1. One Grade 3 CRS at 45 µg dose led to cohort discontinuation; no ICANS observed.","Company to host Immunology Day June 10 with additional CLN-978 multi-dose data and initial velinotamig data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-260640","json":"https://secwatch.observer/filing/0001193125-26-260640.json","markdown":"https://secwatch.observer/filing/0001193125-26-260640.md","text":"https://secwatch.observer/filing/0001193125-26-260640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526260640/0001193125-26-260640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526260640/cgem-20260606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:35:18.201722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}